Induction of ovulation and borderline ovarian cancer - The hormonal connection?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 85, Issue 1, 1999, Pages 71-74

  Shushan, Asher ^a   Paltiel, Ora ^a   Schenker, Joseph G ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Borderline ovarian tumors; Gonadotropin; Infertility; Ovarian cancer; Ovulation induction

Indexed keywords

ESTROGEN RECEPTOR;

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE CLASSIFICATION; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; INFERTILITY THERAPY; MUTATION; OVARY CANCER; OVULATION INDUCTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 0032999558     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00285-1     Document Type: Conference Paper

References (27)

1. DiSaia PJ. Ovarian disorders. In: Scott JR, DiSaia PJ, Hammond CB, Spellacy WN, editors. Danforth's obstetrics and gynecology. Philadelphia: JB Lippincott, 1994.
2. Cramer D.W., Welch W.R., Scully R.E., Wojciechowski C.A. Ovarian cancer and talc: a case-control study. Cancer. 50:1982;372-376.
3. Cramer D.W., Welch W.R., Hutchison G.B., Willett W., Scully R.E. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol. 63:1984;833-838.
4. Fathalla M.F. Incessant ovulation - a factor in ovarian neoplasia? Lancet. 2:1971;163.
5. Fishel S., Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? Br Med J. 299:1989;309-311.
6. Atlas M., Mencjer J. Massive hyperstimulation and borderline malignancy carcinoma of the ovary: A possible association. Acta Obstet Gynecol Scand. 61:1982;261-263.
7. Goldberg G.L., Runowicz C.D. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - Is there a link? Am J Obstet Gynecol. 166:1992;853-854.
8. Shushan A, Brzezinski A, Schenker JG. Hormonal treatments and genital cancer: an update. In: Genazzani AR, Petraglia F, Genazzani AD, editors. Frontiers in gynecologic and obstetric investigation. New York: Parthenon, 1993:163-84.
9. Whittemore A.S., Harris R., Itnyre J. the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 136:1992;1184-1203.
10. Rossing M.A., Daling J.R., Weiss N.S., Moore D.E., Self S.G. Ovarian tumors in a cohort of infertile women. New Engl J Med. 331:1994;771-776.
11. Shushan A., Paltiel O., Iscovich J., Elchalal U., Peretz T., Schenker J.G. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril. 65:1996;13-18.
12. Ron E., Lunenfeld B., Menczer J.et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 125:1987;780-790.
13. Franceschi S., La Vecchia C., Negri E.et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod. 9:1994;1673-1675.
14. Venn A., Watson L., Lumley J., Giles G., King C., Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 346:1995;995-1000.
15. Mosgaard B.J., Lidegaar Ø., Krüger K.S., Schou G., Andersen A.N. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 67:1997;1005-1012.
16. Harris R., Whittemore A.S., Itnyre J. the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol. 136:1992;1204-1211.
17. Parazzini F., Negri E., La Vecchia C., Moroni S., Franceschi S., Crosignani P.G. Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod. 12:1997;2159-2161.
18. Parazzini F., Negri E., La Vecchia C.et al. Treatment for fertility and risk of borderline malignancy. Gynecol Oncol. 68:1998;226-228.
19. International Federation of Fertility Societies. Fertility drugs and ovarian cancer. Fertil Steril 1993;60:406-8.
20. Walters D.E. Ovarian cancer and pregnancy: comment on a paper by Whittemore et al. Fertil Steril. 61:1994;239-242.
21. Spirtas R., Kaufman S.C., Alexander N.J. Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril. 59:1993;291-293.
22. Shapiro S. Risk of ovarian cancer after treatment for infertility. New Eng J Med. 332:1995;1301.
23. Shushan A., Paltiel O., Gordon L., Schenker J.G. Ovarian cancer of low malignant potential is not associated with positive familial history. Am J Obstet Gynecol. 65:1996;13-18.
24. Modan B., Gak E., Bar Sade-Bruchim R.et al. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. J Am Med Assoc. 276:1996;1823-1825.
25. Shushan A., Abeliovich D., Peretz T., Weinberg N., Paltiel O. BRCA1 mutations in women with ovarian cancer. J Am Med Assoc. 277:1997;963.
26. Abu-Jawdeh G.M., Jacobs T.W., Niloff J., Cannistra S.A. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 60:1996;301-307.
27. Iscovich J., Shushan A., Schenker J.G., Paltiel O. The incidence of borderline ovarian tumors in Israel. A population based study. Cancer. 82:1998;147-151.